- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00138307
Correlates of Protection in Ghana
August 26, 2010 updated by: National Institute of Allergy and Infectious Diseases (NIAID)
Immunological Correlates of Protection Against Clinical Malaria in a Cohort of Young Children in the Kassena Nankana District of Ghana
Malaria is a sickness passed from one person to the other by the bite of a mosquito.
In areas of frequent malaria infection, children may develop natural protection against malaria and they are less likely to become sick or die from it as they age.
The purpose of this study is to investigate the body's natural protection against malaria in children by testing their blood.
This information may help investigators develop a malaria vaccine.
The Navrongo Health Research Centre is conducting this study in Ghana.
Three hundred healthy children between the ages of 1 and 5 years will participate in the study for 12 months.
Study procedures will include 7 field worker visits to check on the child's health and obtain a blood sample.
Every two months, a blood sample will be taken from each child to test it for strength against malaria.
Whenever a child is sick, the child will be tested for malaria.
Study Overview
Status
Completed
Conditions
Detailed Description
The principal aim of this study is to identify immunological correlates of naturally acquired immunity to malaria in young children in the process of acquiring clinical immunity.
As a secondary aim, the investigators will study whether allele specific immune responses provide only allele-specific protection against symptomatic infection.
Finally, the investigators will assess the baseline immune responses and the extent to which they are boosted during the malaria transmission season in a population likely to be involved in malaria vaccine trials in the near future.
The overall study design is to enroll 300 healthy children, aged 1-5 years, located in the northern section of the Kassena-Nankana district and to follow them for twelve months, including the entire high malaria transmission season.
They will be evaluated upon enrollment, bimonthly, and at the close of the study by physical examination, malaria smear, hemoglobin determination, and analysis of levels of specific antibody directed against a panel of candidate malaria vaccine antigens.
Throughout the course of the study the children will be followed with passive case detection.
In between the scheduled visits, parents will be encouraged to bring their children to the Paga Health Centre or Navrongo War Memorial Hospital or to a field worker anytime that they believe the child is not well.
At such visits, the child will be evaluated with a morbidity questionnaire including a physical examination.
A blood smear will be taken and a rapid malaria diagnostic test (DiaMed Optimal Rapid Malaria test) and hemoglobin measurement will be performed at the time of the visit.
Treatment decisions will be based on clinical assessment and the result of the rapid malaria test.
The smear result will not be available at the time initial treatment decisions are made.
Children diagnosed with malaria will be treated with standard therapy per Ghana Ministry of Health policy by Ghana Health Service personnel.
Children suffering from severe anemia or from any form of severe malaria will be referred to the Navrongo War Memorial Hospital for definitive treatment, including intravenous anti-malarial therapy and transfusion, if indicated, at no cost to the subject.
At the time of discharge the subject will be evaluated by a study physician with a history and physical, malaria smear and hemoglobin determination.
If in the clinical judgment of the study physician no further treatment is required, the subject will resume participation in the study.
Study Type
Observational
Enrollment
300
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Legon, Ghana
- Noguchi Memorial Institute of Medical Research
-
Navrongo, Ghana
- Navrongo Health Research Centre
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
1 year to 5 years (Child)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Male and female children aged between 1-5 years.
- Willingness of parent or guardian to give and sign a consent form and have the child participate in this study.
- The expectation of continuous residency in the Kassena-Nankana District for the entire study period
Exclusion Criteria:
- Pre-existing chronic disease at the time of enrollment.
- Acute illness at the time of enrollment.
- Hemoglobin less than 6.0g/dL at the time of enrollment.
- Inability of the child's parent or guardian to give informed consent.
- Expectation of possible unavailability to continue participation in the study.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Time Perspectives: Prospective
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Completion
March 1, 2006
Study Registration Dates
First Submitted
August 26, 2005
First Submitted That Met QC Criteria
August 26, 2005
First Posted (Estimate)
August 30, 2005
Study Record Updates
Last Update Posted (Estimate)
August 27, 2010
Last Update Submitted That Met QC Criteria
August 26, 2010
Last Verified
March 1, 2007
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 04-027
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.